Beam Therapeutics Stock Analysis
| BEAM Stock | USD 21.03 0.28 1.35% |
Beam Therapeutics is undervalued with Real Value of 25.72 and Hype Value of 20.93. The main objective of Beam Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Beam Therapeutics is worth, separate from its market price. There are two main types of Beam Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Beam Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Beam Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Beam Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Beam Stock Analysis Notes
About 98.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Beam Therapeutics recorded a loss per share of 4.61. The entity last dividend was issued on the February 4, 2014. The firm had 2:1 split on the October 26, 1990. Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people. For more info on Beam Therapeutics please contact John MBA at 857 327 8775 or go to https://beamtx.com.Beam Therapeutics Investment Alerts
| Beam Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (302.07 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
Beam Therapeutics Upcoming and Recent Events
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Beam Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.09 B.Technical Drivers
As of the 22nd of July, Beam Therapeutics shows the risk adjusted performance of 0.0612, and Mean Deviation of 2.72. Beam Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Beam Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Beam Therapeutics is priced correctly, providing market reflects its regular price of 21.03 per share. Given that Beam Therapeutics has jensen alpha of 0.2166, we suggest you to validate Beam Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.Beam Therapeutics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of Beam Therapeutics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Beam Therapeutics short-term fluctuations and highlight longer-term trends or cycles.
Beam Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Beam Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Beam Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Beam Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Beam Therapeutics Outstanding Bonds
Beam Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Beam Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Beam bonds can be classified according to their maturity, which is the date when Beam Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Beam Therapeutics Predictive Daily Indicators
Beam Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Beam Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 250739.0 | |||
| Daily Balance Of Power | 0.1436 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 21.83 | |||
| Day Typical Price | 21.56 | |||
| Price Action Indicator | (0.65) | |||
| Period Momentum Indicator | 0.28 |
Beam Therapeutics Forecast Models
Beam Therapeutics' time-series forecasting models are one of many Beam Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Beam Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Beam Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Beam Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Beam shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Beam Therapeutics. By using and applying Beam Stock analysis, traders can create a robust methodology for identifying Beam entry and exit points for their positions.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. Beam Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 507 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Beam Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.